

PHYLOGICA

BREAKTHROUGH PEPTIDE THERAPEUTICS

ASX Announcement

11 April 2018

Changes To Board and Management

- **Alan Tribe appointed as Chair of the Board of Directors and acquires 19.9% shareholding in Phylogica**
- **Rohan Hockings appointed as Chief Executive Officer**
- **Stephanie Unwin resigns as Chair and Chief Executive Officer**
- **Michael Williams resigns as Non-Executive Director**

Phylogica (the 'Company') is pleased to announce the appointment of Mr Alan Tribe as the Chairperson of the Company's Board of Directors alongside the appointment of Rohan Hockings as the Company's Chief Executive Officer. Stephanie Unwin will resign from the position of Non-Executive Director and CEO following the Company's next scheduled Board meeting on 27 April 2018 in order to give effect to the changes.

Mr. Tribe brings substantial commercial experience to the Board and a deep interest in Phylogica's delivery platform developed through his time as a major shareholder in the Company. Mr. Tribe has increased his shareholding in the Company to 19.9% to accompany his appointment as Chairperson.

Dr. Hockings holds a Bachelor of Medicine and Bachelor of Surgery with honours as well as a Juris Doctorate. He has worked in both medicine and law including in the equity capital markets division of Freehills. Dr. Hockings has also spent 4 years working with McKinsey & Company on corporate strategy across a range of industries with a particular focus on healthcare. He brings continuity of knowledge of Phylogica through his involvement in the strategic review as well as a background that allows him to bridge the technical and commercial elements of the Company's future. The terms of Mr Hockings engagement will be announced when formalised.

The changes enable the Company to both diversify and accelerate development of the Functional Penetrating Peptide (FPP) delivery platform through the transition from 'proof of concept' cargoes to therapeutic cargoes and towards the clinic.

The Board would like to thank Ms. Unwin for her contribution over the past two years in her capacity as both Chairperson and CEO. Ms. Unwin oversaw the strategic review of the Company in 2017 as well as the delivery of the first in vivo validation of the platform under the new strategic direction. Ms. Unwin will work with Dr. Hockings over coming months in order to ensure a smooth transition with no disruption to the Company's operations.

The Company looks forward to updating the market with additional data in support of the validation of its FPP platform over coming months as previously announced.

ENDS